FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988573614> ?p ?o ?g. }

• W2988573614 endingPage "5255" @default.
• W2988573614 startingPage "5255" @default.
• W2988573614 abstract "Background. Ibrutinib became available for patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in Russia in the end of 2015 based on the results of phase 2 study by M. Wang from MD Anderson Cancer Center (NEJM 2013, Blood 2015). However, pts in routine clinical practice tend to differ significantly from the patients selected for clinical trials, which may lead to poorer results in off study treated patients. Aim. To assess efficacy and toxicity of ibrutinib monotherapy in pts with R/R MCL in routine community clinical practice outside of clinical trials. Materials & Methods. We analyzed the charts of all pts with R/R MCL who started ibrutinib from April 2016 to July 2019 in 7 Moscow's hospitals. The following criteria were used to initiate ibrutinib monotherapy: the age > 18 years, confirmed MCL diagnosis with nuclear hyperexpression of cyclin D1 and/or presence of the t(11;14)(q13;q32); symptomatic relapse or failure to achieve at least PR with a prior regimen. Poor physical status, pancytopenia grade 3-4, infectious complications (except for life-threatening conditions), blastoid variant and the number of previous treatment lines were not regarded as contraindications to ibrutinib therapy. Patients with CNS involvement were excluded from this analysis. Ibrutinib was administered once a day at a dose of 560 mg until progression or intolerable toxicity. Response to therapy was assessed every 2-3 months utilizing CT scan, PET/CT and bone marrow examination were required to confirm CR. Results. 54 pts with R/R MCL received ibrutinib monotherapy between April 2016 and July 2019. 26 pts (48%) were refractory to a prior therapy. The median age was 68 years (range 40-81); 69% of pts were men; ECOG > 2 in 22% of pts. 15 pts (28%) underwent a repeated biopsy before starting ibrutinib. 23 pts (43%) had an aggressive variant of MCL: either blastoid morphology (13/54 at diagnosis and 5/54 after repeated biopsy) or classical morphology with Ki-67>40% (4/54 at diagnosis and 1/54 after repeated biopsy). The median number of previous treatment lines was 2 (1-11). The response was evaluated in 53/54 pts. ORR was 81%, CR rate was 30% in the whole group. Pts with aggressive variants of MCL (group 1) had ORR of 65%, CR rate of 7%. In the group with classical morphology and Ki-67≤40% (group 2) ORR and CR rates were 93% and 47%. 2 pts with a response to therapy stopped ibrutinib early on their own accord, without signs of toxicity above gr.1. The median EFS for all pts was 394 days (95% CI: 261-526). In group 1 the median EFS was 173 days (95% CI: 112-234), in the group 2 the median EFS was 759 days (95% CI: 521-996, p<0.0001). 27 pts (50%) died (25 deaths were MCL-related). The median OS for the entire population studied was 491 days (95% CI: 183-799). The median OS of pts after progression on ibrutinib was disappointingly short - 84 days (95% CI: 30-139). 21 pts (39%) remain on ibrutinib treatment for 10-1119 days (the median duration was 358 days). The most common complications were myalgia and muscle cramps (60%, all gr.1-2), diarrhea (gr.1-2 in 58% and gr.3 in 4%); hemorrhagic complications (65%, all gr. 1-2); skin, nail toxicity and a rash (15%, all gr.1-2) and arrhythmia (9%). Infections were reported in 30% of pts (gr.3 in 6%). Skin/nails toxicity developed mainly after 6 months of ibrutinib intake. In 14 (26 %) pts ibrutinib treatment had to be adjusted (dose reduction or treatment interruption for 3-10 days) due to toxicity and planned surgeries. 4 pts (9%) required dose reduction from 560 to 420 mg. None of ibrutinib recipients had to completely discontinue ibrutinib therapy due to complications (with exception of 2 patients who stopped taking ibrutinib on their own). None of the patients received alloSCT. Conclusion. These data on the use of ibrutinib in actual clinical practice are comparable with the results of international multicenter studies (PCYC-1104, SPARK, and RAY). Favorable toxicity profile and rather short time to antitumor response allow for ibrutinib administration in cases of poor performance status due to disease, low blood count, and even infectious complications. Ibrutinib monotherapy results in the durable disease control in 93% of patients with non-blastoid MCL with the median EFS 25 months, but only 65% with blastoid type with the median EFS 6 months. However, some adverse effects are manifested not earlier than after 6-month treatment, which calls for continuous monitoring, especially when preparing for surgeries. Figure Disclosures Vorobyev: AstraZeneca: Consultancy; Abbvie: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy. Ptushkin:JSC GENERIUM: Research Funding; Alexion Pharmaceuticals, Inc:: Consultancy, Research Funding; Janssen: Consultancy; Roche: Consultancy; AbbVie: Consultancy." @default.
• W2988573614 created "2019-11-22" @default.
• W2988573614 creator A5002077604 @default.
• W2988573614 creator A5009374653 @default.
• W2988573614 creator A5030115487 @default.
• W2988573614 creator A5036770808 @default.
• W2988573614 creator A5040499157 @default.
• W2988573614 creator A5044185386 @default.
• W2988573614 creator A5044377729 @default.
• W2988573614 creator A5057590254 @default.
• W2988573614 creator A5061126953 @default.
• W2988573614 creator A5071809163 @default.
• W2988573614 creator A5077089081 @default.
• W2988573614 creator A5088484827 @default.
• W2988573614 creator A5089481136 @default.
• W2988573614 date "2019-11-13" @default.
• W2988573614 modified "2023-10-14" @default.
• W2988573614 title "Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials" @default.
• W2988573614 doi "https://doi.org/10.1182/blood-2019-126430" @default.
• W2988573614 hasPublicationYear "2019" @default.
• W2988573614 type Work @default.
• W2988573614 sameAs 2988573614 @default.
• W2988573614 citedByCount "0" @default.
• W2988573614 crossrefType "journal-article" @default.
• W2988573614 hasAuthorship W2988573614A5002077604 @default.
• W2988573614 hasAuthorship W2988573614A5009374653 @default.
• W2988573614 hasAuthorship W2988573614A5030115487 @default.
• W2988573614 hasAuthorship W2988573614A5036770808 @default.
• W2988573614 hasAuthorship W2988573614A5040499157 @default.
• W2988573614 hasAuthorship W2988573614A5044185386 @default.
• W2988573614 hasAuthorship W2988573614A5044377729 @default.
• W2988573614 hasAuthorship W2988573614A5057590254 @default.
• W2988573614 hasAuthorship W2988573614A5061126953 @default.
• W2988573614 hasAuthorship W2988573614A5071809163 @default.
• W2988573614 hasAuthorship W2988573614A5077089081 @default.
• W2988573614 hasAuthorship W2988573614A5088484827 @default.
• W2988573614 hasAuthorship W2988573614A5089481136 @default.
• W2988573614 hasBestOaLocation W29885736141 @default.
• W2988573614 hasConcept C121608353 @default.
• W2988573614 hasConcept C126322002 @default.
• W2988573614 hasConcept C143998085 @default.
• W2988573614 hasConcept C2777063308 @default.
• W2988573614 hasConcept C2777525834 @default.
• W2988573614 hasConcept C2777938653 @default.
• W2988573614 hasConcept C2778336483 @default.
• W2988573614 hasConcept C2778461978 @default.
• W2988573614 hasConcept C2778850193 @default.
• W2988573614 hasConcept C2779338263 @default.
• W2988573614 hasConcept C2779382419 @default.
• W2988573614 hasConcept C2779878957 @default.
• W2988573614 hasConcept C2780007613 @default.
• W2988573614 hasConcept C2781413609 @default.
• W2988573614 hasConcept C29730261 @default.
• W2988573614 hasConcept C535046627 @default.
• W2988573614 hasConcept C71924100 @default.
• W2988573614 hasConceptScore W2988573614C121608353 @default.
• W2988573614 hasConceptScore W2988573614C126322002 @default.
• W2988573614 hasConceptScore W2988573614C143998085 @default.
• W2988573614 hasConceptScore W2988573614C2777063308 @default.
• W2988573614 hasConceptScore W2988573614C2777525834 @default.
• W2988573614 hasConceptScore W2988573614C2777938653 @default.
• W2988573614 hasConceptScore W2988573614C2778336483 @default.
• W2988573614 hasConceptScore W2988573614C2778461978 @default.
• W2988573614 hasConceptScore W2988573614C2778850193 @default.
• W2988573614 hasConceptScore W2988573614C2779338263 @default.
• W2988573614 hasConceptScore W2988573614C2779382419 @default.
• W2988573614 hasConceptScore W2988573614C2779878957 @default.
• W2988573614 hasConceptScore W2988573614C2780007613 @default.
• W2988573614 hasConceptScore W2988573614C2781413609 @default.
• W2988573614 hasConceptScore W2988573614C29730261 @default.
• W2988573614 hasConceptScore W2988573614C535046627 @default.
• W2988573614 hasConceptScore W2988573614C71924100 @default.
• W2988573614 hasIssue "Supplement_1" @default.
• W2988573614 hasLocation W29885736141 @default.
• W2988573614 hasOpenAccess W2988573614 @default.
• W2988573614 hasPrimaryLocation W29885736141 @default.
• W2988573614 hasRelatedWork W1994502729 @default.
• W2988573614 hasRelatedWork W2108519805 @default.
• W2988573614 hasRelatedWork W2143935650 @default.
• W2988573614 hasRelatedWork W2215157211 @default.
• W2988573614 hasRelatedWork W2309839179 @default.
• W2988573614 hasRelatedWork W2364127836 @default.
• W2988573614 hasRelatedWork W2597950542 @default.
• W2988573614 hasRelatedWork W2914575774 @default.
• W2988573614 hasRelatedWork W2988573614 @default.
• W2988573614 hasRelatedWork W4296041719 @default.
• W2988573614 hasVolume "134" @default.
• W2988573614 isParatext "false" @default.
• W2988573614 isRetracted "false" @default.
• W2988573614 magId "2988573614" @default.
• W2988573614 workType "article" @default.